Safety, activity, and molecular heterogeneity following neoadjuvant non-pegylated liposomal doxorubicin, paclitaxel, trastuzumab, and pertuzumab in HER2-positive breast cancer (Opti-HER HEART): an open-label, single-group, multicenter, phase 2 trial.
Joaquín GaviláMafalda OliveiraTomás PascualJose Perez-GarciaXavier GonzàlezJordi CanesLaia ParéIsabel CalvoEva CiruelosMontserrat MuñozJuan A VirizuelaIsabel RuizRaquel AndrésAntonia PerellóJerónimo MartínezSerafín MoralesMercedes Marín-AguileraDébora MartínezJuan C QueroAntonio Llombart-CussacAleix PratPublished in: BMC medicine (2019)
Keyphrases
- positive breast cancer
- epidermal growth factor receptor
- metastatic breast cancer
- rectal cancer
- locally advanced
- lymph node
- single cell
- drug delivery
- heart failure
- tyrosine kinase
- cross sectional
- cancer therapy
- atrial fibrillation
- double blind
- squamous cell carcinoma
- clinical trial
- recombinant human
- radiation therapy
- chemotherapy induced